News | Treatment Planning | August 17, 2017

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning

Washington D.C. center will combine treatment planning system with Mevion S250i proton therapy system to deliver advanced intensity modulated proton therapy

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning

August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on the Mevion S250i Proton Therapy System with Hyperscan when the facility opens for treatment later this year. The RayStation treatment planning system will enable the utilization of advanced intensity modulated proton therapy (IMPT) capabilities that are unique to the Hyperscan technology, including multi-leaf collimation with Mevion’s Adaptive Aperture.

The combination of RayStation and Mevion’s Hyperscan technology will enable clinicians at MedStar Georgetown to plan and treat patients with the advantage of very sharp field edges and minimized radiation to critical structures.

RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines features such as multi-criteria optimization tools with full support for 4-D adaptive radiation therapy. It also includes functionality such as RaySearch’s algorithms for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability, according to RaySearch.

For more information: www.raysearchlabs.com

Related Content

Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...